Results 71 to 80 of about 9,833 (206)

Valsartan and Amlodipine Improved Haematological and Biochemical Indices of Vildagliptin-treated Streptozotocin-induced Diabetic Rats [PDF]

Pharmaceutical and Biomedical Research
Background: Diabetes mellitus (DM) and hypertension often coexist in sufferers, which exacerbates the complications of DM. Also, the impacts of antihypertensive medications on the treatment outcomes of DM are not fully understood.
Israel Olapeju Bolanl, Osayemwenre Erharuyi, Abigail M. Akhigbemen, Amenaghawon Imuetinyan Ugiagbe, Edobor Ekugum, Samuel O. Nwusulor, Keziah E. Adudu, Abiodun Falodun   +7 more
doaj  

Sita‐ and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross‐sectional study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Sören Dräger, Claudia Kauderer, Svenja Meyhöfer, Leonie Dräger, Jens U. Marquardt, Ralf J. Ludwig, Stephan Arndt, Katharina Boch, Katja Bieber   +8 more
wiley   +1 more source

Caring for Australians and New Zealanders with kidney Impairment guidelines commentary on the Kidney Disease: Improving Global Outcomes clinical practice guideline for management of diabetes and chronic kidney disease

Internal Medicine Journal, Volume 56, Issue 2, Page 274-279, February 2026.
Abstract Diabetes is a leading cause of kidney failure, and individuals with both diabetes and chronic kidney disease (CKD) experience significantly higher rates of complications and mortality. The international guideline developer Kidney Disease: Improving Global Outcomes (KDIGO) has produced clinical practice guidelines that reflect recent advances ...
Hannah Wallace, Mia E. Abdy, Kathie Anderson, Effie Johns, Thu Nguyen, Carla Scuderi, Vincent Lee, David J. Tunnicliffe, Min Jun, on behalf CARI Guidelines Steering Committee, Emily See, Leanne Brown, Helen Coolican, Jonathan Craig, Vanessa Cullen, Jeffrey Ha, Rathika Krishnasamy, Kelly Lambert, Casey Light, Emmy O'Neill, Hannah Smith, Andrea Viecelli   +21 more
wiley   +1 more source

Patient preference and tolerability of a DPP-4 inhibitor a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study

Therapeutic Advances in Endocrinology and Metabolism, 2015
Objective: The present study aimed to assess the patient preference and tolerability of oral dipeptidyl peptidase-4 inhibitor (vildagliptin) versus injectable glucagon-like peptide-1 analog (liraglutide) in patients with type 2 diabetes mellitus ...
Jörg Lüdemann, Eva D. Dütting, Markus Dworak   +2 more
doaj   +1 more source

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes : systematic review and economic evaluation [PDF]

, 2017
Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose.
Clar, Christine, Clegg, Andrew, Colquitt, Jill, Court, Rachel A., Cummins, Ewen, Holt, Tim, Johnston, Rhona, McGrane, David, O'Hare, J. Paul, Royle, Pamela, Shantikumar, Saran, Tan, Bee K., Uthman, Olalekan A., Waugh, Norman   +13 more
core   +3 more sources

Sulfated Polysaccharides in the Hallmarks of Metabolic Syndrome: Functions and Mechanisms

Food Frontiers, Volume 7, Issue 1, January 2026.
The SPs sources are very diverse, including various fishes, sea cucumbers, seaweeds, etc. These SPs are able to improve the glucose and lipid metabolism disorders, hormonal dysregulation, oxidative stress, inflammatory response, complications, and gut homeostasis of MetS by regulating biochemical indicators related to MetS. ABSTRACT Metabolic syndrome (
Fuqiang Zhao, Chuan Li, Xin Zhang, Kexue Zhu, Chao Zhao, Deming Gong, Lulu Zhu, Yongcheng Li, Jun Cao, Shaoping Nie   +9 more
wiley   +1 more source

PDB28 Economic Evaluation of Vildagliptin As Add-on Therapy to Metformin in Diabetes Mellitus Treatment in China [PDF]

, 2003
This repository item contains a single issue of The ISCIP Analyst, an analytical review journal published from 1996 to 2010 by the Boston University Institute for the Study of Conflict, Ideology, and ...
Adami, Fabian, Beasly, Lt. Col. Kris, Cavan, Susan, Dullea, Scott, Lyons, Paul, Martin, Kate, Montgomery, David, Selyuk, Elena, Shapiro, Ariela   +8 more
core   +12 more sources

Partial non‐adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross‐sectional study using blood plasma analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 186-196, January 2026.
Abstract Aims To evaluate medication adherence in patients with type 2 diabetes (T2D) using plasma drug measurements and assess the clinical impact of partial non‐adherence on glycemic control and complications. Materials and Methods This cross‐sectional study included 641 T2D outpatients attending routine follow‐up visits.
Vojtěch Škop, Ivana Laňková, Simona Antalová, Iva Míšková, Kateřina Malá‐Ládová, Josef Malý, Terezie Pelikánová, Jiří Hricko, Tomáš Čajka, Martin Haluzík   +9 more
wiley   +1 more source

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

Vascular Health and Risk Management, 2008
Chantal Mathieu, Evy DegrandeDepartment of Endocrinology, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose.
Chantal Mathieu, Evy Degrande
doaj  

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Vascular Health and Risk Management, 2012
Sylvie Dejager,1 Anja Schweizer,2 James E Foley31Novartis Pharma SAS, Rueil Malmaison, France; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAbstract: The efficacy and safety of the dipeptidyl ...
Dejager S, Schweizer A, Foley JE
doaj